Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Hormone replacement therapy not recommended for stroke prevention

Hormone replacement therapy (HRT) cannot be recommended for the primary or secondary prevention of stroke, a meta-analysis suggests.

Researchers reviewed 28 randomised controlled trials and concluded that HRT is associated with an increased risk of stroke, in particular ischaemic stroke.

They report that out of the 39,769 patients included in the review 2.7 per cent taking HRT experienced a stroke compared with 2.0 per cent in the control group. They estimate that one person in every 147 people treated with HRT would experience a stroke (number needed to harm).

Overall, HRT use was associated with a 29 per cent increased risk of stroke. The researchers also report that among patients who had a stroke, those taking HRT had a 56 per cent higher frequency of death or incapacity.

The authors acknowledge that there is clinical variation in the studies included. For example, they say that the dose of oestrogen used in some studies may be higher than the usual starting dose in Britain and that several of the trials may have been too short to show a beneficial effect on stroke risk.

Nevertheless, they say that extrapolation of these data would suggest that women at a high risk of stroke, such as those who have had a previous stroke, have coronary heart disease or with multiple vascular risk factors, should stop taking HRT unless there is a strong contrary medical reason (published online in BMJ Online First, 7 January 2005).

However, the study has been criticised by the charity Women’s Health Concern, which says that the analysis is dominated by findings from the Women’s Health Initiative studies, which, it says, are the only studies that individually show a small but significant increase in stroke with HRT use.

The charity points out that two important risk factors for stroke when on HRT are the age of the user and the dose of oestrogen used and says that this review does not address these issues and so provides no new information.

“ Women needing to start HRT should not be frightened off by this new publication, nor should those already taking it for any valid reason be discouraged,” it advises.

Citation: The Pharmaceutical Journal URI: 10018187

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Basic Pharmacokinetics

    Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00Buy now
  • Drugs in Use

    Drugs in Use

    Optimise drug therapy for your patients. These case studies help you bridge the gap between theoretical medicines knowledge and practical applications.

    £43.00Buy now
  • Introducing Palliative Care (IPC 5)

    Introducing Palliative Care (IPC 5)

    A key resource for students, covering the recommended palliative curriculum for medical undergraduates.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.